Judith Ann Clements

List of Publications by Year
in descending order

151 papers	10,077 citations	36303 51 h-index	38395 95 g-index
158 all docs	158 docs citations	158 times ranked	14124 citing authors

#	Article	IF	Citations
1	Epithelialâ€"mesenchymal and mesenchymalâ€"epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 2007, 213, 374-383.	4.1	957
2	Bioengineered 3D platform to explore cellâ€"ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials, 2010, 31, 8494-8506.	11.4	533
3	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
4	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
5	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	21.4	389
6	Type II Transmembrane Serine Proteases. Journal of Biological Chemistry, 2001, 276, 857-860.	3.4	317
7	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
8	The Glandular Kallikrein Family of Enzymes: Tissue Specific Expression and Hormonal Regulation. Endocrine Reviews, 1989, 10, 393-419.	20.1	214
9	Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus. Endocrine Reviews, 2010, 31, 407-446.	20.1	214
10	Can tissue engineering concepts advance tumor biology research?. Trends in Biotechnology, 2010, 28, 125-133.	9.3	208
11	The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 265-312.	6.1	198
12	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
13	Standard Preanalytical Coding for Biospecimens: Review and Implementation of the Sample PREanalytical Code (SPREC). Biopreservation and Biobanking, 2012, 10, 366-374.	1.0	146
14	The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer: From Molecular Mechanisms to Clinical Evidence. International Journal of Molecular Sciences, 2013, 14, 14620-14646.	4.1	146
15	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	2.5	145
16	The Expanded Human Kallikrein (KLK) Gene Family: Genomic Organisation, Tissue-Specific Expression and Potential Functions. Biological Chemistry, 2001, 382, 5-14.	2.5	126
17	Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4. Journal of Biological Chemistry, 2000, 275, 37397-37406.	3.4	125
18	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 2006, 387, 637-41.	2.5	123

#	Article	IF	Citations
19	Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs). Journal of Biological Chemistry, 2008, 283, 12293-12304.	3.4	122
20	Translating tissue engineering technology platforms into cancer research. Journal of Cellular and Molecular Medicine, 2009, 13, 1417-1427.	3.6	122
21	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
22	Candidate gene association studies: a comprehensive guide to useful in silicotools. BMC Genetics, 2013, 14, 39.	2.7	115
23	Expression analysis of ?-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer. International Journal of Cancer, 2002, 100, 228-237.	5.1	111
24	Substrate-Guided Design of a Potent and Selective Kallikrein-Related Peptidase Inhibitor for Kallikrein 4. Chemistry and Biology, 2009, 16, 633-643.	6.0	109
25	The human kallikrein gene family: a diversity of expression and function. Molecular and Cellular Endocrinology, 1994, 99, C1-C6.	3.2	101
26	Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials, 2010, 31, 7928-7936.	11.4	101
27	Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials, 2014, 35, 4108-4115.	11.4	95
28	Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate, 2011, 71, 1198-1209.	2.3	93
29	Localization of a New Prostate-specific Antigen-related Serine Protease Gene, KLK4 , Is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3â€“13.4. Journal of Biological Chemistry, 1999, 274, 23210-23214.	3.4	90
30	Kallikrein-Related Peptidase 7 Promotes Multicellular Aggregation via the Î±5Î²1 Integrin Pathway and Paclitaxel Chemoresistance in Serous Epithelial Ovarian Carcinoma. Cancer Research, 2010, 70, 2624-2633.	0.9	82
31	Identification of Evidence-Based Biospecimen Quality-Control Tools. Journal of Molecular Diagnostics, 2013, 15, 3-16.	2.8	79
32	3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer. PLoS ONE, 2014, 9, e111029.	2.5	79
33	Inhibin a-subunit gene expression in the ovaries of immature female rats is stimulated by pregnant mare serum gonadotrophin. Biochemical and Biophysical Research Communications, 1986, 138, 1191-1195.	2.1	78
34	Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment. PLoS ONE, 2012, 7, e40217.	2.5	75
35	Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 29-39.	6.1	71
36	Arginine Vasopressin (AVP) and AVP-Like Immunoreactivity in Peripheral Tissues. Endocrine Reviews, 1986, 7, 449-460.	20.1	69

#	Article	IF	Citations
37	Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis, 2010, 6, 181-188.	1.2	69
38	Characterization of a novel gene,STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Molecular Carcinogenesis, 2001, 32, 44-53.	2.7	68
39	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
40	Tissue engineered humanized bone supports human hematopoiesisÂinÂvivo. Biomaterials, 2015, 61, 103-114.	11.4	62
41	Estrogen Regulation of Kallikrein Gene Expression in the Rat Anterior Pituitary*. Endocrinology, 1986, 119, 268-273.	2.8	61
42	Localization of Arginine Vasopressin-Neurophysin II Messenger Ribonucleic Acid in the Hypothalamus of Control and Brattleboro Rats by Hybridization Histochemistry with a Synthetic Pentadecamer Oligonucleotide Probe*. Endocrinology, 1985, 116, 2366-2368.	2.8	59
43	Expression of PTRF in PC-3 Cells Modulates Cholesterol Dynamics and the Actin Cytoskeleton Impacting Secretion Pathways. Molecular and Cellular Proteomics, 2012, 11, M111.012245.	3.8	59
44	Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone, 2014, 63, 121-131.	2.9	58
45	Identification and Characterization of KLK14, a Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle. Genomics, 2001, 73, 117-122.	2.9	56
46	Seminal Fluid Characterization for Male Fertility and Prostate Cancer: Kallikrein-Related Serine Proteases and Whole Proteome Approaches. Seminars in Thrombosis and Hemostasis, 2007, 33, 087-099.	2.7	56
47	A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocrine-Related Cancer, 2015, 22, 265-276.	3.1	56
48	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
49	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
50	PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis, 2006, 28, 1032-1039.	2.8	54
51	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
52	A bioengineered 3D ovarian cancer model for the assessment ofÂpeptidaseâ€“mediated enhancement of spheroid growth andÂintraperitoneal spread. Biomaterials, 2013, 34, 7389-7400.	11.4	53
53	Secretome and degradome profiling shows that Kallikreinâ€related peptidases 4, 5, 6, and 7 induce TGFÎ²â€1 signaling in ovarian cancer cells. Molecular Oncology, 2014, 8, 68-82.	4.6	51
54	Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate, 2007, 67, 348-360.	2.3	50

#	Article	IF	Citations
55	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
56	Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. Journal of Investigative Dermatology, 2017, 137, 430-439.	0.7	50
57	Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment. PLoS ONE, 2013, 8, e57056.	2.5	47
58	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	3.3	47
59	MicroRNA Theranostics in Prostate Cancer Precision Medicine. Clinical Chemistry, 2016, 62, 1318-1333.	3.2	47
60	Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Advanced Drug Delivery Reviews, 2014, 79-80, 193-213.	13.7	45
61	Elevated Plasma Levels of Pro-opiomelanocortin-Derived Peptides in Sheep following Hypothalamo-Pituitary Disconnection. Neuroendocrinology, 1986, 44, 508-514.	2.5	42
62	Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer and Metastasis Reviews, 2013, 32, 129-145.	5.9	41
63	TTYH2, a Human Homologue of the Drosophila melanogaster Gene tweety, Is Located on 17q24 and Upregulated in Renal Cell Carcinoma. Genomics, 2001, 77, 200-207.	2.9	40
64	Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group. Biopreservation and Biobanking, 2016, 14, 398-409.	1.0	40
65	A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clinical and Experimental Metastasis, 2014, 31, 435-446.	3.3	39
66	Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry, 2008, 389, 653-668.	2.5	38
67	Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nature Reviews Cancer, 2022, 22, 223-238.	28.4	38
68	Enter the Dragon: The Dynamic and Multifunctional Evolution of Anguimorpha Lizard Venoms. Toxins, 2017, 9, 242.	3.4	37
69	Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?. Biological Chemistry, 2006, 387, 697-705.	2.5	36
70	A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. Rna, 2010, 16, 1156-1166.	3.5	36
71	The Cell Surface Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Contributes to Epidermal Growth Factor Receptor-mediated Cell Migration. Journal of Biological Chemistry, 2012, 287, 9792-9803.	3.4	36
72	Concomitant Dopaminergic and Glucocorticoid Control of Pituitary Proopiomelanocortin Messenger Ribonucleic Acid and Î²-Endorphin Levels*. Endocrinology, 1987, 121, 1689-1696.	2.8	34

#	Article	IF	Citations
73	The Molecular Biology of the Kallikreins and their Roles in Inflammation. , 1997, , 71-97.		34
74	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	3.5	34
75	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecologic Oncology, 2012, 127, 569-578.	1.4	33
76	Delineating breast cancer cell interactions with engineered bone microenvironments. Journal of Bone and Mineral Research, 2013, 28, 1399-1411.	2.8	33
77	MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCER. Journal of Urology, 1999, 161, 1337-1343.	0.4	32
78	The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biological Chemistry, 2006, 387, 707-14.	2.5	32
79	Glucocorticoid Regulation of Proopiomelanocortin Gene Expression in the Pituitary Gland of Hypothalamopituitary Intact and Hypothalamopituitary Disconnected Sheep. Neuroendocrinology, 1989, 50, 280-285.	2.5	31
80	Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology, 1997, 36, 217-220.	2.0	30
81	Epithelial-Mesenchymal Transition in Prostate Cancer and the Potential Role of Kallikrein Serine Proteases. Cells Tissues Organs, 2007, 185, 111-115.	2.3	30
82	Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU International, 2007, 99, 735-742.	2.5	30
83	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 635-643.	1.6	30
84	Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1. Journal of Proteome Research, 2016, 15, 2466-2478.	3.7	30
85	Regulation of Follicle-Stimulating Hormone Î² and Common Î±-Subunit Messenger Ribonucleic Acid by Gonadotropin-Releasing Hormone and Estrogen in the Sheep Pituitary. Neuroendocrinology, 1989, 50, 321-326.	2.5	29
86	Kallikrein gene expression in estrogen-induced pituitary tumors. Molecular and Cellular Endocrinology, 1988, 60, 225-232.	3.2	28
87	Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors. Biological Chemistry, 2016, 397, 1237-1249.	2.5	28
88	Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts. Biomaterials, 2019, 220, 119402.	11.4	28
89	ACTIVATION OF THE KALLIKREIN KININ SYSTEM IN INTERSTITIAL CYSTITIS. Journal of Urology, 1999, 162, 129-134.	0.4	27
90	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27

#	Article	IF	Citations
91	Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. British Journal of Cancer, 2018, 119, 1-9.	6.4	27
92	Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Research, 2019, 7, 13.	11.4	27
93	Naloxone, Adrenalectomy, and Steroid Replacement:Evidence against a Role for Circulating Î²-Endorphin in Food Intake*. Endocrinology, 1981, 108, 189-192.	2.8	26
94	Direct Progesterone Receptor and Indirect Androgen Receptor Interactions with the Kallikrein-Related Peptidase 4 Gene Promoter in Breast and Prostate Cancer. Molecular Cancer Research, 2009, 7, 129-141.	3.4	26
95	Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biological Chemistry, 2012, 393, 1365-1390.	2.5	24
96	Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget, 2016, 7, 4939-4948.	1.8	24
97	Regulation of liver angiotensinogen mRNA by glucocorticoids and thyroxine. Molecular and Cellular Endocrinology, 1989, 61, 147-156.	3.2	23
98	A novel transcript from the KLKP1 gene is androgen regulated, downâ€regulated during prostate cancer progression and encodes the first nonâ€serine protease identified from the human kallikrein gene locus. Prostate, 2008, 68, 381-399.	2.3	23
99	Reflections on the tissue kallikrein and kallikrein-related peptidase family â€“ from mice to men â€“ what have we learnt in the last two decades?. Biological Chemistry, 2008, 389, 1447-1454.	2.5	22
100	KALLIKREINS AND KININS IN INFLAMMATORY-LIKE EVENTS IN THE REPRODUCTIVE TRACT. Pharmacological Research, 1997, 35, 537-540.	7.1	21
101	Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 169-179.	4.2	21
102	Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget, 2016, 7, 2572-2584.	1.8	21
103	Foot Shock Analgesia. Neuroendocrinology, 1982, 35, 236-241.	2.5	20
104	Temporal and Tissue-Specific Expression of Kallikrein (Klk) Genes and Identification of a Novel Klk Messenger Ribonucleic Acid Transcript during Early Development in the Mouse1. Biology of Reproduction, 1999, 61, 621-628.	2.7	20
105	The human tissue kallikreins (KLKs 1â€“3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology, 1999, 45, 83-88.	2.0	20
106	A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer, 2011, 11, 119.	2.6	20
107	In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Science Advances, 2021, 7, .	10.3	20
108	The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2352-2365.	2.5	18

#	Article	IF	Citations
109	Kallikrein-Related Peptidase 10 (KLK10) Expression and Single Nucleotide Polymorphisms in Ovarian Cancer Survival. International Journal of Gynecological Cancer, 2010, 20, 529-536.	2.5	18
110	Genetic Association of the KLK4 Locus with Risk of Prostate Cancer. PLoS ONE, 2012, 7, e44520.	2.5	18
111	Tissue-specific promoter utilisation of the kallikrein-related peptidase genes,KLK5andKLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry, 2008, 389, 99-109.	2.5	17
112	Correlation of the expression of human kallikreinâ€related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head and Neck, 2011, 33, 566-572.	2.0	17
113	Long Terminal Repeats Act as Androgen-Responsive Enhancers for the PSA-Kallikrein Locus. Endocrinology, 2012, 153, 3199-3210.	2.8	17
114	Breast Cancer Cells Induce Osteolytic Bone Lesions In vivo through a Reduction in Osteoblast Activity in Mice. PLoS ONE, 2013, 8, e68103.	2.5	17
115	Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer. Biological Chemistry, 2014, 395, 1127-1132.	2.5	17
116	Kallikreinâ€related peptidase 4 induces cancerâ€associated fibroblast features in prostateâ€derived stromal cells. Molecular Oncology, 2017, 11, 1307-1329.	4.6	17
117	Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. Clinical Chemistry, 2019, 65, e1-e9.	3.2	17
118	Development of Anti-hLH Antibodies after Therapy with Posterior Pituitary Extract*. Journal of Clinical Endocrinology and Metabolism, 1978, 47, 1-8.	3.6	16
119	Fusion transcript loci share many genomic features with non-fusion loci. BMC Genomics, 2015, 16, 1021.	2.8	16
120	Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Molecular and Cellular Proteomics, 2019, 18, 818a-836.	3.8	16
121	The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biological Chemistry, 2012, 393, 403-412.	2.5	15
122	MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer. Clinical Chemistry, 2019, 65, 771-780.	3.2	15
123	A Replication Study Examining Novel Common Single Nucleotide Polymorphisms Identified Through a Prostate Cancer Genome-wide Association Study in a Japanese Population. American Journal of Epidemiology, 2011, 174, 1391-1395.	3.4	14
124	A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. Journal of the American Chemical Society, 2021, 143, 8911-8924.	13.7	14
125	Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. PLoS ONE, 2011, 6, e26527.	2.5	14
126	Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 269-81.	0.7	14

#	Article	IF	Citations
127	The Expression of the Kallikrein Gene Family in the Rat Pituitary: Oestrogen Effects and the Expression of an Additional Family Member in the Neurointermediate Lobe. Journal of Neuroendocrinology, 1989, 1, 198-203.	2.6	13
128	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	2.5	13
129	Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases. Biological Chemistry, 2014, 395, 977-990.	2.5	13
130	Kallikrein 4 (KLK4), A New Member of the Human Kallikrein Gene Family Is Up-Regulated By Estrogen and Progesterone in the Human Endometrial Cancer Cell Line, KLE. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2323-2323.	3.6	13
131	Kallikrein-Related Peptidase 3(KLK3/PSA) Single Nucleotide Polymorphisms and Ovarian Cancer Survival. Twin Research and Human Genetics, 2011, 14, 323-327.	0.6	11
132	Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells. Endocrinology, 2012, 153, 3179-3189.	2.8	11
133	Proteomic and other analyses to determine the functional consequences of deregulated kallikreinâ€related peptidase (<scp>KLK</scp>) expression in prostate and ovarian cancer. Proteomics - Clinical Applications, 2014, 8, 403-415.	1.6	10
134	Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases. American Journal of Cancer Research, 2017, 7, 2257-2274.	1.4	10
135	Oestrogen administration and the expression of the kallikrein gene family in the rat submandibular gland. The Journal of Steroid Biochemistry, 1990, 35, 55-60.	1.1	9
136	Post-Translational Processing of Pro-Opiomelanocortin in the Brattleboro (di/di) Rat Pituitary. Neuroendocrinology, 1988, 48, 603-610.	2.5	8
137	Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 2010, 391, 461-6.	2.5	8
138	In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B. Biological Chemistry, 2016, 397, 1299-1305.	2.5	8
139	Lycopene's Effects on Cancer Cell Functions within Monolayer and Spheroid Cultures. Nutrition and Cancer, 2016, 68, 350-363.	2.0	7
140	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
141	Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency. Scientific Reports, 2017, 7, 6789.	3.3	6
142	Gonadal steroids and anterior lobe dynorphin in the male rat. The Journal of Steroid Biochemistry, 1989, 32, 303-308.	1.1	5
143	KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. Cancers, 2020, 12, 3501.	3.7	5
144	STRESS, DOPAMINERGIC BLOCKADE AND MEDIAN EMINENCE-NEUROINTERMEDIATE LOBE CATECHOLAMINE DEPLETION: EFFECTS ON HYPOTHALAMIC, PITUITARY AND PLASMA IMMUNOREACTIVE ?-ENDORPHIN. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 221-229.	1.9	4

#	Article	IF	Citations
145	Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population. Quality of Life Research, 2015, 24, 2183-2193.	3.1	3
146	A computational analysis of the genetic and transcript diversity at the kallikrein locus. Biological Chemistry, 2016, 397, 1307-1313.	2.5	3
147	Single Nucleotide Polymorphisms (SNPs). , 2014, , 55-80.		2
148	The Human Tissue Kallikrein and Kallikrein-related Peptidase Family. , 2013, , 2747-2756.		1
149	Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy. Expert Review of Proteomics, 2017, 14, 1119-1130.	3.0	1
150	Transforming the Future of Treatment for Ovarian Cancer. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
151	Kallikrein-related Peptidase 15 (Prostinogen). , 2013, , 2814-2817.		0